Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Arg Vasopressin
2. Arg-vasopressin
3. Arginine Vasopressin
4. Argipressin Tannate
5. Vasopressin, Arginine
1. Arginine Vasopressin
2. 113-79-1
3. Argipressine
4. Pitressin
5. Beta-hypophamine
6. 8-arginine-vasopressin
7. Argipressin Tannate
8. Vasopressin (arginine Form)
9. Arginine-vasopressin
10. Chebi:34543
11. Vasophysin
12. Arg-vasopressin
13. Chembl373742
14. (arg8)-vasopressin
15. [arg8]-vasopressin
16. (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
17. 8-l-arginine Vasopressin
18. Argipresina
19. Argipressina
20. Argipressinum
21. Avp
22. Arg8-vasopressin
23. Argipressin [inn]
24. Argipressina [dcit]
25. Ncgc00166306-01
26. Argipressin [inn:ban]
27. 8-l-arginine-vasopressin
28. Argipresina [inn-spanish]
29. Argipressine [inn-french]
30. Argipressinum [inn-latin]
31. Unii-y4907o6mfd
32. Rindervasopressin
33. [3h]vasopressin
34. Einecs 204-035-4
35. 3-(phenylalanine)-8-arginineoxytocin
36. Arg8-vasopressin;avp
37. Arginine-8-vasopressin
38. Argipressin Or Lypressin
39. [8-arginine]vasopressin
40. [3h]argipressin Tannate
41. Antidiuretic Hormone (adh)
42. Arginine Vasopressin (avp)
43. Argipressin Tannate [usan]
44. Arginine Antidiuretic Hormone
45. Dsstox_cid_28324
46. Dsstox_rid_82752
47. Dsstox_gsid_48349
48. Schembl43139
49. Vasopressin, 8-l-arginine-
50. [cyclo S-s]cyfqncprg-nh2
51. Gtpl2168
52. Y4907o6mfd
53. Dtxsid0048349
54. Schembl17874853
55. Bdbm35667
56. Tox21_113037
57. Bdbm50044777
58. Mfcd00076738
59. Ncgc00166306-02
60. Ncgc00188439-01
61. Cas-113-79-1
62. H-cys-tyr-phe-gln-asn-cys-pro-arg-gly-nh2
63. Oxytocin, 3-(l-phenylalanine)-8-l-arginine-
64. Vasopressin, 8-l-arginine- (7ci,8ci,9ci)
65. Roxybenzyl-6,9,12,15,18-pentaoxo- (6ci)
66. 113a791
67. Q183011
68. Cys-tyr-phe-gln-asn-cys-pro-arg-gly-nh2[disulfide Bridge: 1-6]
69. (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]pyrrolidine-2-carboxamide
70. 1,2-dithia-5,8,11,14,17-pentaazacycloeicosane-10-propionamide, 19-amino-13-benzyl-7-(carbamoylmethyl)-4-[2-[[1-[(carbamoylmethyl)carbamoyl]-4-guanidinobutyl]carbamoyl]-1-pyrrolidinylcarbonyl]-16-p-hyd
71. 1-{[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-l-prolyl-l-arginylglycinamide
72. Glycinamide, L-cysteinyl-l-tyrosyl-l-phenylalanyl-l-glutaminyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-arginyl-, Cyclic (1>6)-disulfide
Molecular Weight | 1084.2 g/mol |
---|---|
Molecular Formula | C46H65N15O12S2 |
XLogP3 | -4.8 |
Hydrogen Bond Donor Count | 14 |
Hydrogen Bond Acceptor Count | 16 |
Rotatable Bond Count | 19 |
Exact Mass | 1083.43785492 g/mol |
Monoisotopic Mass | 1083.43785492 g/mol |
Topological Polar Surface Area | 515 Ų |
Heavy Atom Count | 75 |
Formal Charge | 0 |
Complexity | 2070 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
Antidiuretic Agents
Agents that reduce the excretion of URINE, most notably the octapeptide VASOPRESSINS. (See all compounds classified as Antidiuretic Agents.)
Hemostatics
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : Complete
Rev. Date : 2017-09-29
Pay. Date : 2017-08-24
DMF Number : 28532
Submission : 2014-08-01
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-07-13
Pay. Date : 2018-05-04
DMF Number : 32769
Submission : 2018-05-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-09-11
Pay. Date : 2018-08-27
DMF Number : 33119
Submission : 2018-08-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25736
Submission : 2012-01-24
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-01-19
Pay. Date : 2022-11-25
DMF Number : 37634
Submission : 2022-12-03
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2025-07-25
Pay. Date : 2025-07-15
DMF Number : 42073
Submission : 2025-06-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5410
Submission : 1984-04-04
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-03-06
Pay. Date : 2017-11-27
DMF Number : 32146
Submission : 2017-10-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-03-02
Pay. Date : 2017-10-04
DMF Number : 32116
Submission : 2017-10-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27577
Submission : 2013-12-19
Status : Inactive
Type : II
About the Company : HRV Pharma is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...
About the Company : Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide p...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : BCN Peptides is a privately own company completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications. We are a customer oriented...
About the Company : JIN DUN Medical Research Institute is affiliated to Shanghai JIN DUN Industrial Co., Ltd., headquartered in Shanghai, adjacent to Hongqiao High-speed Railway Station and Hongqiao I...
About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...
About the Company : Piramal Pharma Solutions (PPS) is a CDMO that provides end-to-end solutions for drug development and manufacturing across the drug life cycle to its clients in North America, Europ...
About the Company : Shenzhen JYMed Technology Co.,Ltd is a high-tech enterprise engaged in research and development, manufacturing and commercialization of peptides based products, including active ph...
About the Company : With over a decade of experience in the Pharmaceutical and Health sector, HNB stands as a contemporary company specializing in the exploration, advancement, manufacturing, processi...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
The launch of authorized generic version of Par Pharmaceutical’s VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market was approved by the U.S. Food and Drug Administration (USFDA).
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vasopressin-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 09, 2022
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (v...
Details : The launch of authorized generic version of Par Pharmaceutical’s VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market was approved by the U.S. Food and Drug Administration (USFDA).
Product Name : Vasopressin-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
February 09, 2022
Details:
Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vasostrict-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2025
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Gland Pharma receives FDA approval for Vasopressin in 5% Dextrose RTU Injection
Details : Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
Product Name : Vasostrict-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 26, 2025
Details:
Vasopressin is a Protein drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2025
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vasopressin is a Protein drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 04, 2025
Details:
Vasopressin is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock, Septic.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Hormone
Sponsor: University of Utah
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2024
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : University of Utah
Deal Size : Inapplicable
Deal Type : Inapplicable
Vasopressin for Septic Shock Pragmatic Trial
Details : Vasopressin is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock, Septic.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 22, 2024
Details:
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines and Vasostrict is a RFLD.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vasostrict-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 14, 2023
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio
Details : Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines and Vasostrict is a RFLD.
Product Name : Vasostrict-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
June 14, 2023
Details:
Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shocks, such as due to post-cardiotomy or sepsis, and remain hypotensive despite fluids and catecholamines.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vasopressin-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2022
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Pharma Arm Gets Final US FDA Nod for Vasopressin injection
Details : Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shocks, such as due to post-cardiotomy or sepsis, and remain hypotensive despite fluids and catecholamines.
Product Name : Vasopressin-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 16, 2022
Details:
Vasopressin injection 1mL is a generic version of the antidiuretic hormone Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vasopressin-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 11, 2022
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Launches 4 New Generic Products, Including Vasopressin Single-dose
Details : Vasopressin injection 1mL is a generic version of the antidiuretic hormone Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Product Name : Vasopressin-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
August 11, 2022
Details:
In August, the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vasopressin-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 29, 2021
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
Details : In August, the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.
Product Name : Vasopressin-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 29, 2021
Details:
The U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vasopressin-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Par Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 29, 2021
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Par Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.
Product Name : Vasopressin-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 29, 2021
Details:
This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.
Lead Product(s): Arginine Vasopressin,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vasopressin-Generic
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2021
Lead Product(s) : Arginine Vasopressin,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
Details : This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.
Product Name : Vasopressin-Generic
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 15, 2021
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
52
PharmaCompass offers a list of Arginine Vasopressin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Arginine Vasopressin manufacturer or Arginine Vasopressin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Arginine Vasopressin manufacturer or Arginine Vasopressin supplier.
PharmaCompass also assists you with knowing the Arginine Vasopressin API Price utilized in the formulation of products. Arginine Vasopressin API Price is not always fixed or binding as the Arginine Vasopressin Price is obtained through a variety of data sources. The Arginine Vasopressin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Argipressin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Argipressin, including repackagers and relabelers. The FDA regulates Argipressin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Argipressin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Argipressin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Argipressin supplier is an individual or a company that provides Argipressin active pharmaceutical ingredient (API) or Argipressin finished formulations upon request. The Argipressin suppliers may include Argipressin API manufacturers, exporters, distributors and traders.
click here to find a list of Argipressin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Argipressin DMF (Drug Master File) is a document detailing the whole manufacturing process of Argipressin active pharmaceutical ingredient (API) in detail. Different forms of Argipressin DMFs exist exist since differing nations have different regulations, such as Argipressin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Argipressin DMF submitted to regulatory agencies in the US is known as a USDMF. Argipressin USDMF includes data on Argipressin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Argipressin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Argipressin suppliers with USDMF on PharmaCompass.
A Argipressin written confirmation (Argipressin WC) is an official document issued by a regulatory agency to a Argipressin manufacturer, verifying that the manufacturing facility of a Argipressin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Argipressin APIs or Argipressin finished pharmaceutical products to another nation, regulatory agencies frequently require a Argipressin WC (written confirmation) as part of the regulatory process.
click here to find a list of Argipressin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Argipressin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Argipressin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Argipressin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Argipressin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Argipressin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Argipressin suppliers with NDC on PharmaCompass.
Argipressin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Argipressin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Argipressin GMP manufacturer or Argipressin GMP API supplier for your needs.
A Argipressin CoA (Certificate of Analysis) is a formal document that attests to Argipressin's compliance with Argipressin specifications and serves as a tool for batch-level quality control.
Argipressin CoA mostly includes findings from lab analyses of a specific batch. For each Argipressin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Argipressin may be tested according to a variety of international standards, such as European Pharmacopoeia (Argipressin EP), Argipressin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Argipressin USP).